The estimated Net Worth of Carl Desantis is at least $232 Million dollars as of 12 August 2022. Carl Desantis owns over 103,952 units of iBio Inc stock worth over $1,349,000 and over the last 21 years Carl sold IBIO stock worth over $230,857,750.
Sign up
Carl Desantis IBIO stock SEC Form 4 insiders trading
Carl has made over 26 trades of the iBio Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Carl sold 103,952 units of IBIO stock worth $9,575,019 on 12 August 2022.
The largest trade Carl's ever made was selling 2,928,310 units of iBio Inc stock on 14 June 2021 worth over $183,019,375. On average, Carl trades about 176,471 units every 90 days since 2004. As of 12 August 2022 Carl still owns at least 710,000 units of iBio Inc stock.
You can see the complete history of Carl Desantis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Carl Desantis's mailing address?
Carl's mailing address filed with the SEC is 109 S.E. 5TH AVENUE, SUITE 200, , DELRAY BEACH, FL, 33483.
Insiders trading at iBio Inc
Over the last 14 years, insiders at iBio Inc have traded over $99,626,328 worth of iBio Inc stock and bought 15,716,013 units worth $10,660,994 . The most active insiders traders include Capital Ltd Portfolio Servi..., Carl Desantis, and William D Clark. On average, iBio Inc executives and independent directors trade stock every 98 days with the average trade being worth of $1,893,515. The most recent stock trade was executed by Martin Brenner on 1 November 2023, trading 4,881 units of IBIO stock currently worth $1,318.
What does iBio Inc do?
ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.
What does iBio Inc's logo look like?
Complete history of Carl Desantis stock trades at Celsius Inc and iBio Inc
iBio Inc executives and stock owners
iBio Inc executives and other stock owners filed with the SEC include:
-
Thomas Isett,
Chairman of the Board, Chief Executive Officer -
Thomas F. Isett III,
CEO, Pres & Chairman -
Robert Kay,
Interim Secretary, Interim Treasurer, Director -
Randy Joe Maddux,
Chief Operating Officer -
Dr. Martin B. Brenner D.V.M., Ph.D.,
Chief Scientific Officer -
Robert Erwin,
President -
Robert B. Kay,
Interim Sec. & Interim Treasurer -
James Hill,
Independent Director -
John McKey,
Independent Director -
Seymour Flug,
Independent Director -
Glenn Chang,
Independent Director -
Stephen Kilmer,
Investor Relations -
Gary Sender,
Independent Director -
Alexandra Kropotova,
Independent Director -
Linda Armstrong,
Independent Director -
John Delta,
Principal Financial Officer, Principal Accounting Officer -
Carlos Picosse,
Chief Exec. Officer of IBio Brazil -
Dr. Melissa Berquist Ph.D.,
VP and Head of Vaccines & Animal Health -
Lisa Middlebrook,
Chief HR Officer -
Robert Matthew Lutz,
Chief Financial & Bus. Officer -
Mark A Giannone,
Chief Financial Officer -
Kenneth Bryan Dart,
10% owner -
Carl Desantis,
10% owner -
Philip K. Russell,
Director -
Arthur Y Elliott,
Director -
Capital Ltd Portfolio Servi...,
-
Ryan E Terence,
Chief Scientific Officer -
Randy Joe Maddux,
Chief Operating Officer -
Robert Matthew Lutz,
See Remarks -
James P. Mullaney,
Chief Financial Officer -
Evert B. Schimmelpennink,
Director -
E Gerald Kay,
10% owner -
Jules A. Musing,
Director -
William D Clark,
Director -
Martin Brenner,
See Remarks -
Felipe Duran,
Chief Financial Officer